0000899243-20-034282.txt : 20201217 0000899243-20-034282.hdr.sgml : 20201217 20201217160511 ACCESSION NUMBER: 0000899243-20-034282 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201215 FILED AS OF DATE: 20201217 DATE AS OF CHANGE: 20201217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HENDERSON MICHAEL THOMAS CENTRAL INDEX KEY: 0001779990 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 201396147 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-15 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001779990 HENDERSON MICHAEL THOMAS C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 Chief Business Officer Stock Option (Right to Buy) 3.07 2020-12-15 4 A 0 4456 0.00 A 2030-04-01 Common Stock 4456 4456 D Stock Option (Right to Buy) 3.07 2020-12-15 4 A 0 3137 0.00 A 2030-07-20 Common Stock 3137 3137 D Stock Option (Right to Buy) 42.80 2020-12-15 4 A 0 2199 0.00 A 2030-09-29 Common Stock 2199 2199 D The option was acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in a privately-held subsidiary of the Issuer. The number of option shares and per share exercise price of the new option was determined based on the number of shares and per share exercise price of the subsidiary option at a certain exchange ratio. 1,671 shares subject to the stock option were vested as of the date of acquisition, 93 shares shall vest on January 1, 2021, and 2,692 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. 1,177 shares subject to the stock option were vested as of the date of acquisition, 65 shares shall vest on January 1, 2021, and 1,895 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. 825 shares subject to the stock option were vested as of the date of acquisition, 46 shares shall vest on January 1, 2021, and 1,328 shares shall vest in monthly installments over the next 29 months thereafter, in each case so long as the Reporting Person continues to have a service relationship with the Issuer or a Subsidiary on each such date. /s/ Tara Condon, Attorney-in-Fact 2020-12-17